These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 25311215)

  • 1. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
    Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
    J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
    J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology
    J Mol Diagn; 2013 Jul; 15(4):415-53. PubMed ID: 23562183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Mol Diagn; 2018 Mar; 20(2):129-159. PubMed ID: 29398453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
    Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
    Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline.
    Rekhtman N; Leighl NB; Somerfield MR
    J Oncol Pract; 2015 Mar; 11(2):135-6. PubMed ID: 25515718
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.
    DiStasio M; Chen Y; Rangachari D; Costa DB; Heher YK; VanderLaan PA
    Clin Lung Cancer; 2017 Sep; 18(5):e349-e356. PubMed ID: 28377205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer.
    Mino-Kenudson M; Mark EJ
    Arch Pathol Lab Med; 2011 May; 135(5):655-64. PubMed ID: 21526964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    Arch Pathol Lab Med; 2018 Mar; 142(3):321-346. PubMed ID: 29355391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
    Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.
    Dacic S
    J Clin Pathol; 2013 Oct; 66(10):870-4. PubMed ID: 23801495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
    Camidge DR; Kono SA; Flacco A; Tan AC; Doebele RC; Zhou Q; Crino L; Franklin WA; Varella-Garcia M
    Clin Cancer Res; 2010 Nov; 16(22):5581-90. PubMed ID: 21062932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Working Group Meeting on ALK diagnostics in lung cancer.
    Cooper W; Fox S; O'Toole S; Morey A; Frances G; Pavlakis N; O'Byrne K; Dettrick A; Leong T; Rathi V; Spagnolo D; Hemmings C; Singh M; Moffat D; Tsao MS; Wilner K; Buller R; Pitman Lowenthal S; Arifeen S; Binko J; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():11-7. PubMed ID: 24673736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Thorac Oncol; 2018 Mar; 13(3):323-358. PubMed ID: 29396253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.
    Buchholz TA; Somerfield MR; Griggs JJ; El-Eid S; Hammond ME; Lyman GH; Mason G; Newman LA
    J Clin Oncol; 2014 May; 32(14):1502-6. PubMed ID: 24711553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.
    Vikas P; Messersmith H; Compton C; Sholl L; Broaddus RR; Davis A; Estevez-Diz M; Garje R; Konstantinopoulos PA; Leiser A; Mills AM; Norquist B; Overman MJ; Sohal D; Turkington RC; Johnson T
    J Clin Oncol; 2023 Apr; 41(10):1943-1948. PubMed ID: 36603179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.